News

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...
Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript
Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...
Ophthalmology Advisor6h
Identifying Uveitis Type Can Save Patients’ Vision, And Maybe Even Their Lives
Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...